Retinoblastoma (Rb) protein expression and resistance in squamous cell lung carcinomas

Anticancer Research

Volumn 16, Issue 2, 1996, Pages 891-894

  Volm, M ^a   Stammler, G ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Immunohistochemistry; Resistance; Retinoblastoma protein; Squamous cell lung carcinomas

Indexed keywords

DOXORUBICIN; GLUTATHIONE TRANSFERASE; RETINOBLASTOMA PROTEIN;

ADULT; ARTICLE; CLINICAL TRIAL; DIAGNOSTIC VALUE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA, SQUAMOUS CELL; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; GLUTATHIONE TRANSFERASE; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; NEOPLASM PROTEINS; P-GLYCOPROTEIN; RETINOBLASTOMA PROTEIN;

EID: 0029954402     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Knudson AG: Hereditary cancer, oncogenes and antioncogenes. Cancer Res 45: 1437-1443, 1 985.
2. Yokola J, Akiyama T, Fung YK, Benedict WF, Namha Y, Hanaoka M, Wada M, Terasaki T, Shimosato Y, Sugimura T and Terada M: Altered expression of the retinoblastoma (RB) gene in small-cell carcinoma of the lung. Oncogene 3: 471-475, 1988.
3. Xu H-J, Hu S-X, Cagle PT, Moore GE and Benedict WF: Absence of retinoblastoma protein expression in primary non-small cell lung carcinomas. Cancer Res 51: 2735-2739, 1991.
4. Reissmann PT, Koga H, Takahashi R, Figlin RA, Holmes EC, Piantadosi S, Cordon-Cardo C and Slamon DJ: Inactivation of the retinoblastoma susceptibility gene in non-small cell lung cancer. Oncogene 8: 1913-1919, 1993.
5. Shimizu E, Coxon A, Otterson GA, Steinberg SM, Kratzke RA, Kim YW, Fedorko J, Oie H, Johnson BE, Mulshine JL, Minna JD, Gazdar AF and Kaye FJ: RB protein status and clinical correlation from 171 cell lines representing lung cancer, extrapulmonary small cell carcinoma, and mesothelioma. Oncogene 9: 2441-2448, 1994.
6. Riordan JR and Ling V: Genetic and biochemical characterisation of multidrug resistance. Pharmacol Ther 28: 51-57, 1985.
7. Morrow CS and Cowan K: Glutathione S-transferase and drug resistance. Cancer Cells 2: 15-22, 1990.
8. Volm M, Mattern J and Samsel B: Relationship of inherent resistance to doxorubicin, proliferative activity and expression of P-glycoprotein 170, and glutathione S-transferase-π in human lung tumors. Cancer 70: 764-769, 1992.
9. Efferth T, Mattern, J and Volm M: Immunohistochemical detection of P-glycoprotein, glutathione S-transferase-π and DNA topoisomerase II in human tumors. Oncology 49: 368-375, 1992.
10. Percy ME: Catalase: an old enzyme with a new role? Can J Biochem Cell Biol 62: 1006-1014, 1984.
11. Volm M, Koomägi R, Mattern J and Stammler G: Heat shock (hsp 70) and resistance proteins in non-small cell lung carcinomas. Cancer Lett 95: 195-200, 1995.
12. World Health Organization: Histological typing of lung tumors. Tumori 6: 253-272, 1981.
13. Carr DT and Mountain CF : Staging lung cancer. In: Straus MJ (ed). Lung Cancer. Clinical Diagnosis and Treatment. Grune and Stratton, New York, 1977. p. 151-161.
14. Group for sensitivity testing of tumors (KSST): In vitro short term test to determine the resistance of human tumors to chemotherapy. Cancer 48: 2127-2135, 1981.
15. Volm M, Bak M, Efferth T, Lathan B and Mattern J: Immunocytochemical detection of a resistance-associated glycoprotein in tissue culture cells, ascites tumors and human tumor xenografts by Mab 265/F4. Anticancer Res 8: 531-536, 1988.
16. Volm M, Kästei M, Mattern J and Efferth T: Expression of resistance factors (P-glycoprotein, glutathione S-transferase and topoisomerase II) and their interrelationship to protooncogene products in renal cell carcinoma. Cancer 71: 3981-3987, 1993.
17. Xu HJ, Quinlan DC, Davidson AG, Hu SX, Summers CL, Li J and Benedict WF: Altered retinoblastoma protein expression and prognosis in early-stage non-small cell lung carcinoma. J Natl Cancer Inst 86: 695-699, 1994.
18. Cance WG, Brennan MF, Dudas ME, Huang CM and Cardo CC: Altered expression of the retinoblastoma gene-product in human sarcomas. N Engl J Med 323: 1457-1452, 1990.
19. Cordon-Cardo CC, Wertinger D, Petrylak D, Dalbagni G, Fair WR, Fuks Z and Reuter VE: Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. J Natl Cancer Inst 84: 1251-1256, 1992.
20. Logothetis CJ, Xu H-J, Ro JY, Hu SX, Sahin A, Ordonez N and Benedict WI: Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. J Natl Cancer Inst 84: 1256-1261, 1992.
21. Volm M, Kaufmann M and Mattern J: Results obtained using a short term radionucleotide assay and clinical correlation. In: Human tumor drug sensitivity testing in vitro (Dendy PP and Hill BT, eds). London, Academic Press, 1983, pp251-258.
22. Khoo SK, Hurst T, Webb MJ, Dickie G, Kearsley I, Parsons PG and Mackay EV: Clinical value of in vitro drug sensitivity testing based on short-term effects on DNA and RNA metabolism in ovarian cancer. J Surg Oncol 41: 201-205, 1989.